Finance / Investment
Finance and Investment in the BioPharma Market
In this section you will find information products covering Finance and Investment within the biopharmaceutical market, including latest technologies, company profiles, biopharmaceuticals, market data and information covering Europe, the UK, North America and Asia.Stay up-to-date with new products added to this category »
| Title | Publication Date | Price |
|---|---|---|
|
Pharma Corporate Venture Capital (CVC): key players, new conditions and big opportunities |
September 2009 | £295 |
|
Forecasting for the Pharmaceutical Industry |
October 2006 | £75 |
|
Financial Markets Research: Palatin Technologies' Bremelanotide Competition and regulatory risk cloud potential |
September 2006 | £2195 |
|
Financial Markets Research: Sirona Dental Systems Likely struggle for impressive annual growth despite strong reputation and technology |
September 2006 | £2195 |
|
Financial Markets Research: Spectrum Pharmaceuticals' Oral Satraplatin Oral therapy to take share in second-line hormone-refractory prostate cancer market |
September 2006 | £2195 |
|
Pharmaceutical CME Measuring Program Effectiveness in the Compliance Environment |
September 2006 | £2800 |
|
Financial Markets Research: Renovis, Inc.'s NXY-059 Safety profile and unmet need could drive approval |
August 2006 | £2195 |
|
Financial Markets Research: Santarus, Inc.'s Zegerid Fast-acting formulation gaining momentum in GERD |
August 2006 | £2195 |
|
Financial Markets Research: Indevus Pharmaceuticals' Sanctura XR Last-to-market entrant unlikely to make an impact in crowded OAB market |
August 2006 | £2195 |
|
Financial Markets Research: Endo Pharmaceuticals’ Lidoderm Physician survey indicates increased use likely to fuel above-consensus sales growth |
August 2006 | £2195 |
|
Financial Markets Research: ASCO Review Part IICO 2006 Annual Meeting A summary of highlights presented at the ASCO 2006 Annual Meeting |
August 2006 | £2195 |
|
Financial Markets Research: ASCO Review Part II A summary of highlights presented at the ASCO 2006 Annual Meeting |
August 2006 | £2195 |
|
Financial Markets Research: Bausch & Lomb's Contact Lens Solution Withdrawal ReNu MultiPlus likely to struggle in attempt to regain market share |
August 2006 | £2195 |
|
Alternative Financial Solutions for Medical Technology Acquisition |
May 2005 | £2495 |
|
Venture Capital Analyst: Health Care Edition |
January 2005 | £705 |
|
VentureWire Lifescience Daily newsletter |
January 2005 | £275 |
|
Guide to Venture Capital in European Biopharma |
September 2004 | £430 |
|
Venture Capital Analyst Health Care Sourcebook, The |
April 2004 | £260 |
